RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Inhibitor Therapeutics Stock

Inhibitor Therapeutics ROE 2024

Inhibitor Therapeutics ROE

-0.57

Ticker

INTI

ISIN

US45720M1053

WKN

A2PQRT

In 2024, Inhibitor Therapeutics's return on equity (ROE) was -0.57, a -139.88% increase from the 1.44 ROE in the previous year.

Inhibitor Therapeutics Aktienanalyse

What does Inhibitor Therapeutics do?

Inhibitor Therapeutics Inc is a biopharmaceutical company specializing in the development of innovative therapies for cancer and autoimmune diseases. The company was founded in the USA in 2008 and has since established itself as a leading player in the biotech industry. The history of Inhibitor Therapeutics Inc began with the discovery of a promising molecule called ITI-007, which could represent a novel treatment option for schizophrenia. After extensive preclinical tests and clinical studies, ITI-007 was eventually approved by the FDA and brought to market. The medication has proven to be very successful and is used by many patients worldwide. Today, Inhibitor Therapeutics Inc's business model includes several different divisions. In addition to schizophrenia therapy, the company focuses on the development of innovative cancer therapies based on the blockage of enzymes and proteins responsible for tumor growth. The company utilizes a wide range of technologies to develop the best therapies for different types of cancer. Inhibitor Therapeutics Inc's products also include a range of diagnostics and biomarkers that contribute to the early detection and treatment of cancer. These technologies enable personalized medicine and help improve the effectiveness of therapies. Overall, the goal of Inhibitor Therapeutics Inc is to improve the lives of millions of people through groundbreaking innovations in cancer and autoimmune therapy. The company works closely with leading scientific institutions and clinics to translate the latest research findings into clinical practice. An important part of Inhibitor Therapeutics Inc's corporate culture is promoting diversity and inclusion. The company actively strives to create a work environment that is open and inclusive, where every employee has the opportunity to reach their full potential. Overall, Inhibitor Therapeutics Inc is an emerging company specializing in the development of innovative therapies for cancer and autoimmune diseases. With a wide range of technologies and products, a strong corporate culture, and a dedicated team of employees, the company is well-positioned to continue growing in the coming years and make its vision of better health for all a reality. Inhibitor Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Inhibitor Therapeutics's Return on Equity (ROE)

Inhibitor Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Inhibitor Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Inhibitor Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Inhibitor Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Inhibitor Therapeutics stock

What is the ROE (Return on Equity) of Inhibitor Therapeutics this year?

The ROE of Inhibitor Therapeutics this year is -0.57 undefined.

How has the Return on Equity (ROE) of Inhibitor Therapeutics developed compared to the previous year?

The ROE of Inhibitor Therapeutics has increased by -139.88% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Inhibitor Therapeutics?

A high ROE indicates that Inhibitor Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Inhibitor Therapeutics?

A low ROE can indicate that Inhibitor Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Inhibitor Therapeutics affect the company?

A change in ROE (Return on Equity) of Inhibitor Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Inhibitor Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Inhibitor Therapeutics?

Some factors that can influence Inhibitor Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Inhibitor Therapeutics pay?

Over the past 12 months, Inhibitor Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Inhibitor Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Inhibitor Therapeutics?

The current dividend yield of Inhibitor Therapeutics is .

When does Inhibitor Therapeutics pay dividends?

Inhibitor Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Inhibitor Therapeutics?

Inhibitor Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Inhibitor Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Inhibitor Therapeutics located?

Inhibitor Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Inhibitor Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Inhibitor Therapeutics from 11/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/1/2024.

When did Inhibitor Therapeutics pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Inhibitor Therapeutics in the year 2023?

In the year 2023, Inhibitor Therapeutics distributed 0 USD as dividends.

In which currency does Inhibitor Therapeutics pay out the dividend?

The dividends of Inhibitor Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Inhibitor Therapeutics

Our stock analysis for Inhibitor Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Inhibitor Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.